Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic

References

• What is the U.S. opioid epidemic? 2019 [cited 2019 Sept 18]; Available from: https://www.hhs.gov/opioids/about-the-epidemic/index.html.
   Google Scholar
• Rudd RA, Aleshire N, Zibbell JE, et al. Increases in drug and opioid overdose deaths–United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–1382.
   Google Scholar
• Seth P, Scholl L, Rudd RA, et al. Overdose deaths involving opioids, cocaine, and psychostimulants United States, 2015-2016 (Reprinted from American Journal Of Transplantation, vol 67, pg 349-358, 2018). Am J Transplant. 2018;18(6):1556–1568.
   Google Scholar
• Scholl L, Seth P, Kariisa M, et al. Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419–1427.
   Google Scholar
• Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006;81(2):103–107.
   Google Scholar
• What is addiction? 2019; Available from: https://www.psychiatry.org/patients-families/addiction/what-is-addiction.
   Google Scholar
• Veilleux JC, Colvin PJ, Anderson J, et al. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30(2):155–166.
   Google Scholar
• Manchikanti L, Helm S, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9–38.
   Google Scholar
• Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13–20.
   Google Scholar
• Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci. 2009;10(8):561–572.
   Google Scholar
• Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12(2):483–488.
   Google Scholar
• Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011;12(11):652–669.
   Google Scholar
• Maher CE, Martin TJ, Childers SR. Mechanisms of mu opioid receptor/G-protein desensitization in brain by chronic heroin administration. Life Sci. 2005;77(10):1140–1154.
   Google Scholar
• Zarrindast MR, Ahmadi S, Haeri-Rohani A, et al. GABA(A) receptors in the basolateral amygdala are involved in mediating morphine reward. Brain Res. 2004;1006(1):49–58.
   Google Scholar
• Glass MJ, Kruzich PJ, Colago EEO, et al. Increased AMPA GluR1 receptor subunit labeling on the plasma membrane of dendrites in the basolateral amygdala of rats self-administering morphine. Synapse. 2005;58(1):1–12.
   Google Scholar
• Upadhyay J, Maleki N, Potter J, et al. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain. 2010;133(7):2098–2114.
   Google Scholar
• Younger JW, Chu LF, D’Arcy NT, et al. Prescription opioid analgesics rapidly change the human brain. Pain. 2011;152(8):1803–1810.
   Google Scholar
• Cicero TJ, Ellis MS. The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse. Dialogues Clin Neurosci. 2017;19(3):259–269.
   Google Scholar
• Phillips DM. JCAHO pain management standards are unveiled. Joint commission on accreditation of healthcare organizations. Jama. 2000;284(4):428–429.
   Google Scholar
• Inciardi JA, Surratt HL, Cicero TJ, et al. Prescription opioid abuse and diversion in an urban community: the results of an ultrarapid assessment. Pain Med. 2009;10(3):537–548.
   Google Scholar
• Daniulaityte R, Falck R, Carlson RG. “I’m not afraid of those ones just ‘cause they’ve been prescribed”: perceptions of risk among illicit users of pharmaceutical opioids. Int J Drug Policy. 2012;23(5):374–384.
   Google Scholar
• Back SE, Lawson KM, Singleton LM, et al. Characteristics and correlates of men and women with prescription opioid dependence. Addict Behav. 2011;36(8):829–834.
   Google Scholar
• Rigg KK, Ibanez GE. Motivations for non-medical prescription drug use: a mixed methods analysis. Journal of Substance Abuse Treatment. 2010;39(3):236–247.
   Google Scholar
• McCabe SE, Boyd CJ, Cranford JA, et al. Motives for nonmedical use of prescription opioids among high school seniors in the United States: self-treatment and beyond motives for opioid use in US high school seniors. JAMA Pediatr. 2009;163(8):739–744.
   Google Scholar
• Goldner EM, Lusted A, Roerecke M, et al. Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses. Addict Behav. 2014;39(3):520–531.
   Google Scholar
• Manchikanti L, Giordano, PhD J, Boswell, MD, PhD MV, et al. Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients. J Opioid Manag. 2007;3(2):89–100.
   Google Scholar
• Brown BB, Clasen DR, Eicher SA. Perceptions of peer pressure, peer conformity dispositions, and self-reported behavior among adolescents. Dev Psychol. 1986;22(4):521–530.
   Google Scholar
• Farre M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict. 1991;86(12):1601–1606.
   Google Scholar
• Roy SD, Flynn GL. Solubility and related physicochemical properties of narcotic analgesics. Pharm Res. 1988;5(9):580–586.
   Google Scholar
• Mazak K, Noszal B, Hosztafi S. Advances in the physicochemical profiling of opioid compounds of therapeutic interest. ChemistryOpen. 2019;8(7):879–887.
   Google Scholar
• Hatsukami DK, Fischman MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? Jama. 1996;276(19):1580–1588.
   Google Scholar
• Evangelista Vaz R, Draganov DI, Rapp C, et al. Preliminary pharmacokinetics of tramadol hydrochloride after administration via different routes in male and female B6 mice. Vet Anaesth Analg. 2018;45(1):111–122.
   Google Scholar
• Marsch LA, Bickel WK, Badger GJ, et al. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther. 2001;299(3):1056–1065.
   Google Scholar
• Mumford GK, Evans SM, Fleishaker JC, et al. Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther. 1995;57(3):356–365.
   Google Scholar
• Shram MJ, Sathyan G, Khanna S, et al. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol. 2010;30(1):25–33.
   Google Scholar
• Setnik B, Roland CL, Cleveland JM, et al. The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011;12(4):618–631.
   Google Scholar
• Vaughn B, Brown C, Lawler J, et al. The relationship between the pharmacokinetics of morphine abuse-deterrent, extended-release, injection-molded tablets and pharmacodynamic outcomes in oral and intranasal human abuse potential studies. J Pain. 2017;18(4):S35.
   Google Scholar
• Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70(13):1657–1675.
   Google Scholar
• Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem. 2004;73:953–990.
   Google Scholar
• Contet C, Kieffer BL, Befort K. Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol. 2004;14(3):370–378.
   Google Scholar
• Halikere A, Popova D, Scarnati MS, et al. Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons. Mol Psychiatry. 2019.
   Google Scholar
• Darcq E, Kieffer BL. Opioid receptors: drivers to addiction? Nat Rev Neurosci. 2018;19(8):499–514.
   Google Scholar
• Stoops WW, Hatton KW, Lofwall MR, et al. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl). 2010;212(2):193–203.
   Google Scholar
• Walsh SL, Nuzzo PA, Lofwall MR, et al. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008;98(3):191–202.
   Google Scholar
• Comer SD, Sullivan MA, Whittington RA, et al. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology. 2008;33(5):1179–1191.
   Google Scholar
• Zacny JP, Lichtor SA. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology (Berl). 2008;196(1):105–116.
   Google Scholar
• Filizola M, Villar HO, Loew GH. Molecular determinants of non-specific recognition of δ, μ, and κ opioid receptors. Bioorg Med Chem. 2001;9(1):69–76.
   Google Scholar
• Raynor K, Kong H, Chen Y, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994;45(2):330–334.
   Google Scholar
• Zawilska JB. An expanding world of novel psychoactive substances: opioids. Front Psychiatry. 2017;8(110).
   Google Scholar
• Christrup LL, Foster D, Popper L, et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008;30(3):469–481.
   Google Scholar
• Mazer-Amirshahi M, Motov S, Nelson LS. Hydromorphone use for acute pain: misconceptions, controversies, and risks. J Opioid Manag. 2018;14(1):61–71.
   Google Scholar
• Elliott JA, Smith HS. Handbook of acute pain management. Boca Raton, FL: CRC Press; 2016.
   Google Scholar
• Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133–53.
   Google Scholar
• Treillet E, Laurent S, Hadjiat Y. Practical management of opioid rotation and equianalgesia. J Pain Res. 2018;11:2587–2601.
   Google Scholar
• Baldwin N, Gray R, Goel A, et al. Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: an observational analysis. Drug Alcohol Depend. 2018;185:322–327.
   Google Scholar
• Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: exploring users’ perceptions of fentanyl-adulterated and -substituted ‘heroin’. Int J Drug Policy. 2017;46:146–155.
   Google Scholar
• Peterson BL, Schreiber S, Fumo N, et al. Opioid deaths in Milwaukee County, Wisconsin 2013-2017: the primacy of heroin and fentanyl. J Forensic Sci. 2019;64(1):144–148.
   Google Scholar
• Slavova S, Costich JF, Bunn TL, et al. Heroin and fentanyl overdoses in Kentucky: epidemiology and surveillance. Int J Drug Policy. 2017;46:120–129.
   Google Scholar
• D’Errico S. Commentary. Fentanyl-related death and the underreporting risk. J Forensic Leg Med. 2018;60:35–37.
   Google Scholar
• Armenian P, Vo KT, Barr-Walker J, et al. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology. 2018;134(Pt A):121–132.
   Google Scholar
• Ronel N, Levy-Cahana M. Growing-up with a substance-dependent parent: development of subjective risk and protective factors. Subst Use Misuse. 2011;46(5):608–619.
   Google Scholar
• Kendler KS, Karkowski LM, Neale MC, et al. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry. 2000;57(3):261–269.
   Google Scholar
• Merikangas KR, Stolar M, Stevens DE, et al. Familial transmission of substance use disorders. Arch Gen Psychiatry. 1998;55(11):973–979.
   Google Scholar
• Xian H, Chantarujikapong SI, Scherrer JF, et al. Genetic and environmental influences on posttraumatic stress disorder, alcohol and drug dependence in twin pairs. Drug Alcohol Depend. 2000;61(1):95–102.
   Google Scholar
• Mistry CJ, Bawor M, Desai D, et al. Genetics of opioid dependence: a review of the genetic contribution to opioid dependence. Curr Psychiatry Rev. 2014;10(2):156–167.
   Google Scholar
• Zhang H, Kranzler HR, Yang B-Z, et al. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry. 2008;13(5):531–543.
   Google Scholar
• Hou QF, Li SB. Potential association of DRD2 and DAT1 genetic variation with heroin dependence. Neurosci Lett. 2009;464(2):127–130.
   Google Scholar
• Duaux E, Gorwood P, Griffon N, et al. Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. Mol Psychiatry. 1998;3(4):333–336.
   Google Scholar
• Kotler M, Cohen H, Segman R, et al. Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Mol Psychiatry. 1997;2(3):251–254.
   Google Scholar
• Dalley JW, Fryer TD, Brichard L, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science. 2007;315(5816):1267–1270.
   Google Scholar
• Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998;95(16):9608–9613.
   Google Scholar
• Mayer P, Rochlitz H, Rauch E, et al. Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport. 1997;8(11):2547–2550.
   Google Scholar
• Jia W, Shi JG, Wu B, et al. Polymorphisms of brain-derived neurotrophic factor associated with heroin dependence. Neurosci Lett. 2011;495(3):221–224.
   Google Scholar
• Lachman HM, Fann CSJ, Bartzis M, et al. Genomewide suggestive linkage of opioid dependence to chromosome 14q. Hum Mol Genet. 2007;16(11):1327–1334.
   Google Scholar
• Hancock DB, Levy JL, Gaddis NC, et al. Cis-expression quantitative trait loci mapping reveals replicable associations with heroin addiction in OPRM1. Biol Psychiatry. 2015;78(7):474–484.
   Google Scholar
• Cheng Z, Zhou H, Sherva R, et al. Genome-wide association study identifies a regulatory variant of RGMA associated with opioid dependence in European Americans. Biol Psychiatry. 2018;84(10):762–770.
   Google Scholar
• Gelernter J, Kranzler HR, Sherva R, et al. Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry. 2014;76(1):66–74.
   Google Scholar
• Li D, Zhao H, Kranzler HR, et al. Genome-wide association study of copy number variations (CNVs) with opioid dependence. Neuropsychopharmacology. 2015;40(4):1016–1026.
   Google Scholar
• Nelson EC, Agrawal A, Heath AC, et al. Evidence of CNIH3 involvement in opioid dependence. Mol Psychiatry. 2016;21(5):608–614.
   Google Scholar
• Dennis BB, Bawor M, Thabane L, et al. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One. 2014;9(1):e86114.
   Google Scholar
• Egervari G, Landry J, Callens J, et al. Striatal H3K27 acetylation linked to glutamatergic gene dysregulation in human heroin abusers holds promise as therapeutic target. Biol Psychiatry. 2017;81(7):585–594.
   Google Scholar
• Sun H, Maze I, Dietz DM, et al. Morphine epigenomically regulates behavior through alterations in histone h3 lysine 9 dimethylation in the nucleus accumbens. J Neurosci. 2012;32(48):17454–17464.
   Google Scholar
• Doehring A, Oertel BG, Sittl R, et al. Chronic opioid use is associated with increased DNA methylation correlating with increased clinical pain. Pain. 2013;154(1):15–23.
   Google Scholar
• Kozlenkov A, Jaffe A, Timashpolsky A, et al. DNA methylation profiling of human prefrontal cortex neurons in heroin users shows significant difference between genomic contexts of hyper- and hypomethylation and a younger epigenetic age. Genes (Basel). 2017;8(6):152.
   Google Scholar
• Nielsen DA, Yuferov V, Hamon S, et al. Increased OPRM1 DNA methylation in lymphocytes of methadone-maintained former heroin addicts. Neuropsychopharmacology. 2009;34(4):867–873.
   Google Scholar
• Walters CL, Blendy JA. Different requirements for cAMP response element binding protein in positive and negative reinforcing properties of drugs of abuse. J Neurosci. 2001;21(23):9438–9444.
   Google Scholar
• Browne CJ, Godino A, Salery M, et al. Epigenetic mechanisms of opioid addiction. Biol Psychiatry. 2020 Jan 1;87(1):22–23.
   Google Scholar
• Pergolizzi JV Jr, LeQuang JA, Taylor R, et al. Designing safer analgesics: a focus on mu-opioid receptor pathways. Expert Opin Drug Discov. 2018;13(10):965–972.
   Google Scholar
• Fundytus ME, Schiller PW, Shapiro M, et al. Attenuation of morphine tolerance and dependence with the highly selective delta-opioid receptor antagonist TIPP[psi]. Eur J Pharmacol. 1995;286(1):105–108.
   Google Scholar
• Zhu Y, King MA, Schuller AGP, et al. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron. 1999;24(1):243–252.
   Google Scholar
• Banks ML. The rise and fall of kappa-opioid receptors in drug abuse research. Handb Exp Pharmacol. 2019.
   Google Scholar
• Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000;67(5–6):347–364.
   Google Scholar
• Roxane. Methadone HCl tablets USP (Dolophine HCl CII), prescribing information.2006. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2006/006134s028lbl.pdf.
   Google Scholar
• Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth. 1985;57(2):192–196.
   Google Scholar
• Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825–834.
   Google Scholar
• Brown SM, Holtzman M, Kim T, et al. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology. 2011;115(6):1251–1260.
   Google Scholar
• Fishman J, Roffwarg H, Hellman L. Disposition of naloxone-7,8,3H in normal and narcotic-dependent men. J Pharmacol Exp Ther. 1973;187(3):575–580.
   Google Scholar
• Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther. 2012;50(5):360–367.
   Google Scholar
• Kerr D, Kelly A-M, Dietze P, et al. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009;104(12):2067–2074.
   Google Scholar
• Kelly A-M, Kerr D, Koutsogiannis Z, et al. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005;182(1):24–27.
   Google Scholar
• Ryan SA, Dunne RB. Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review. Pain Manag. 2018;8(3):231–245.
   Google Scholar
• Codd EE, Shank RP, Schupsky JJ, et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263–1270.
   Google Scholar
• Chatterjie N, Fujimoto JM, Inturrisi CE, et al. Isolation and stereochemical identification of a metabolite of naltrexone from human urine. Drug Metab Dispos. 1974;2(5):401–405.
   Google Scholar
• Liu JC, Ma JD, Morello CM, et al. Naltrexone metabolism and concomitant drug concentrations in chronic pain patients. J Anal Toxicol. 2014;38(4):212–217.
   Google Scholar
• Alkermes I. Naltrexone for extended-release injectable suspension (VIVITROL), prescribing information. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021897s045lbl.pdf#page=32
   Google Scholar
• Bruce RD, Moody DE, Altice FL, et al. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2013;6(3):249–269.
   Google Scholar
• Meemken L, Hanhoff N, Tseng A, et al. Drug-drug interactions with antiviral agents in people who inject drugs requiring substitution therapy. Ann Pharmacother. 2015;49(7):796–807.
   Google Scholar
• Volpe DA, Xu Y, Sahajwalla CG, et al. Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018;107(12):2983–2991.
   Google Scholar
• Fanucchi L, Springer SA, Korthuis PT. Medications for treatment of opioid use disorder among persons living with HIV. Curr HIV/AIDS Rep. 2019;16(1):1–6.
   Google Scholar
• Picard N, Cresteil T, Djebli N, et al. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005;33(5):689–695.
   Google Scholar
• AlRabiah H, Ahad A, Mostafa GAE, et al. Effect of naltrexone hydrochloride on cytochrome P450 1A2, 2C9, 2D6, and 3A4 activity in human liver microsomes. Eur J Drug Metab Pharmacokinet. 2018;43(6):707–713.
   Google Scholar
• Fihlman M, Hemmilä T, Hagelberg NM, et al. Voriconazole greatly increases the exposure to oral buprenorphine. Eur J Clin Pharmacol. 2018;74(12):1615–1622.
   Google Scholar
• Fihlman M, Hemmilä T, Hagelberg NM, et al. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. Eur J Clin Pharmacol. 2016;72(11):1363–1371.
   Google Scholar
• McCance-Katz EF, Moody DE, Morse GD, et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis. 2006;43(Suppl 4):S224–34.
   Google Scholar
• McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007;91(2–3):269–278.
   Google Scholar
• Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. Aids. 2006;20(5):783–784.
   Google Scholar
• Megarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences. Toxicol Rev. 2006;25(2):79–85.
   Google Scholar
• Pergolizzi JV Jr, Raffa RB, Taylor R, et al. Abuse-deterrent opioids: an update on current approaches and considerations. Curr Med Res Opin. 2018;34(4):711–723.
   Google Scholar
• Timeline of selected FDA activities and significant events addressing opioid misuse and abuse. Food and Drug administration, Silver Spring, MD; 2019. [cited 2020 Feb 16]. Available from: https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-opioid-misuse-and-abuse
   Google Scholar
• Litman RS, Pagan OH, Cicero TJ. Abuse-deterrent opioid formulations. Anesthesiology. 2018;128(5):1015–1026.
   Google Scholar
• Tidgewell, K. Pain Therapeutics: Current and Future Treatment Paradigms. In: ChemMedChem, Charlotte Allerton, Editor. 2014;9:855-855. doi:10.1002/cmdc.201400039
   Google Scholar
• Elvidge S FDA turns down Mallinckrodt application for reformulated oxycodone. 2018 [cited 2020 Jan 17]; Available from: https://www.biopharmadive.com/news/fda-turns-down-mallinckrodt-application-for-reformulated-oxycodone/544290/.
   Google Scholar
• Trevena. 2020.
   Google Scholar
• http://investors.acurapharm.com/news-releases/news-release-details/acura-pharmaceuticals-advances-ltx-03-and-its-limitxtm
   Google Scholar
• https://www.fda.gov/media/121222/download
   Google Scholar
• http://acurapharm.com/otherproductsindevelopment/
   Google Scholar
• https://www.sec.gov/Archives/edgar/data/786947/000114420415056790/v421134_ex99-1.htm
   Google Scholar
• http://www.annualreports.com/HostedData/AnnualReportArchive/a/NASDAQ_ACUR_2009.pdf
   Google Scholar
• http://acurapharm.com/products/acurox-tablets/
   Google Scholar
• Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse. (2019, September 25). In U.S. Food & Drug Administration. Available from: https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-opioid-misuse-and-abuse
   Google Scholar
• Litman RS, Pagan OH, Cicero TJ. Abuse-deterrent opioid formulations. Anesthesiology. 2018 May;128(5):1015–1026.
   Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). [2017, November]. In U.S. food & drug administration. Available from: https://www.fda.gov/media/96643/download
   Google Scholar
• Raffa RB, Pergolizzi JV, Muñiz E Designing opioids that deter abuse.
   Google Scholar
• http://www.nrpharma.com/products/NRP369.htm
   Google Scholar
• http://www.nrpharma.com/products/NRP290.htm
   Google Scholar
• https://www.sec.gov/Archives/edgar/data/1586105/000104746915002296/a2223665z10-k.htm
   Google Scholar
• Nucynta ER abuse profile: an evaluation of abuse and route of administration among individuals receiving substance abuse treatment.
   Google Scholar
• NECEPAC ADF Draft. Available from: https://icer-review.org/wp-content/uploads/2016/08/NECEPAC_ADF_Final_Report_08_08_17.pdf
   Google Scholar
• https://www.fda.gov/news-events/press-announcements/fda-approves-first-buprenorphine-implant-treatment-opioid-dependence
   Google Scholar
• https://www.sublocade.com/how-sublocade-works
   Google Scholar
• https://www.suboxone.com/treatment/suboxone-film
   Google Scholar
• https://www.drugs.com
   Google Scholar
• https://www.nektar.com/pipeline/rd-pipeline/nktr-181
   Google Scholar
• https://d1io3yog0oux5.cloudfront.net/_9a5b3f6942e7dadc825709b2c2a32d9e/trevena/db/707/6063/pdf/1.09.20-TRVN_overview_nonconf_JPM_vF.pdf
   Google Scholar
• Good CB, Manolis C, Shrank W. There’s little evidence abuse-deterrent opioids work. Why should we use them? STAT. 2017: Boston, MA.
   Google Scholar
• Rice JB, Kirson NY, Shei A, et al. Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data. Appl Health Econ Health Policy. 2014;12(4):435–446.
   Google Scholar
• Abuse-deterrent formulations of opioids: effectiveness and value. New England: ©Institute for Clinical and Economic Review; 2017.
   Google Scholar
• Harris SC, Cipriano A, Kapil RP, et al. Oral abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med. 2017 Jul 1;18(7):1278–1291.
   Google Scholar
• Smith MD, Webster LR, Lawler J, et al. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus extended-release morphine administered orally in nondependent recreational opioid users. Pain Med. 2017 May 1;18(5):898–907.
   Google Scholar
• US Food and Drug Administration (FDA). Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets) Package Insert. Cited from Mar, 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205777lbl.pdf
   Google Scholar
• Setnik B, Bass A, Bramson C, et al. Abuse potential study of alo-02 (extended-release oxycodone surrounding sequestered naltrexone) compared with immediate-release oxycodone administered orally to nondependent recreational opioid users. Pain Med. 2017 Jun 1;18(6):1077–1088.
   Google Scholar
• Kopecky EA, Fleming AB, Levy-Cooperman N, et al. Oral human abuse potential of oxycodone DETERx® (Xtampza® ER). J Clin Pharmacol. 2016;57(4):500–512.DOI: https://doi.org/10.1002/jcph.833
   Google Scholar
• Bond M, Darwish M, Ma Y, et al. Evaluation of the abuse potential of an hydrocodone extended-release bitartrate tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users. Drug Alcohol Depend. 2015;156:13.
   Google Scholar
• Setnik B, Sommerville K, Goli V, et al. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users. Pain Med. 2013;14(8):1173–1186.
   Google Scholar
• Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009;29(12):777–790.
   Google Scholar
• Bond M, Schoedel K, Rabinovich-Guilatt L, et al. Evaluation of the relative intranasal abuse potential of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users. J Pain. 2015;16(4):S82.
   Google Scholar
• Harris SC, Perrino PJ, Smith I, et al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol. 2014;54(4):468–477.
   Google Scholar
• Webster LR, Kopecky EA, Smith MD, et al. Double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodone. Pain Med. 2016;17(6):1112–1130.
   Google Scholar
• Setnik B, Bramson C, Bass A, et al. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users. J Clin Pharmacol. 2015;55(12):1351–1361.
   Google Scholar
• Harris SC, Cipriano A, Colucci SV, et al. Intranasal abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med. 2016;17(5):820–831.
   Google Scholar
• Setnik B, Goli V, evy-Cooperman NL, et al. Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. Pain Res Manag. 2013;18(4):e55–e62.
   Google Scholar
• Webster LR, Pantaleon C, Shah MS, et al. A randomized, double-blind, double-dummy, placebo-controlled, intranasal drug liking study on a novel abuse-deterrent formulation of morphine-morphine ARER. Pain Med. 2017 Jul 1;18(7):1303–1313.
   Google Scholar
• Webster LR, Smith MD, Lawler J, et al. Human abuse potential of an Abuse-Deterrent (AD), Extended-Release (ER) morphine product candidate (morphine-ader injection-molded tablets) vs extended-release morphine administered intranasally in nondependent recreational opioid users. Pain Med. 2017 Sep 1;18(9):1695-1705.
   Google Scholar
• Peacock A, Degenhardt L, Hordern A, et al. Methods and predictors of tampering with a tamper- resistant controlled-release oxycodone formulation. Int J Drug Policy. 2015;26(12):1265–1272.
   Google Scholar
• Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14(10):1122–1130.
   Google Scholar
• Severtson SG, Ellis MS, Kurtz SP, et al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend. 2016;168:219–229.
   Google Scholar
• Coplan PM, Chilcoat HD, Butler SF, et al. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther. 2016;100(3):275–286.
   Google Scholar
• Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin. JAMA Psychiatry. 2015;72(5):424–429.
   Google Scholar
• Cicero TJ, Ellis MS, Kasper ZA. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs. Pain. 2016;157(6):1232–1238.
   Google Scholar
• Cassidy TA, DasMahapatra P, Black RA, et al. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med. 2014;15(3):440–451.
   Google Scholar
• Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351–358.
   Google Scholar
• Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187–189.
   Google Scholar
• Jones CM, Muhuri PK, Lurie PG. Trends in the nonmedical use of oxycontin, United States, 2006-2013. Clin J Pain. 2017 May;33(5):452–461.
   Google Scholar
• De Veaugh-Geiss A, Coplan P, Chilcoat H, et al. Changes in nonmedical use of oxycontin® after reformulation with abuse deterrent properties. Postgrad Med. 2016;128:22–23.
   Google Scholar
• Kadakia A, Coplan P. Decrease in diagnosed abuse, addiction, and opioid poisoning among patients prescribed opioids after introduction of oxycontin with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2015;24:472–473.
   Google Scholar
• Institute for clinical and economic review, 2017. Draft evidence report – abuse deterrent formulations of opioids: effectiveness and value
   Google Scholar
• Larochelle MR, Zhang F, Ross-Degnan D, et al. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med. 2015;175(6):978–987.
   Google Scholar
• Sessler NE, Downing JM, Kale H, et al. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014;23(12):1238–1246.
   Google Scholar
• Sessler NE, Downing JM, Kale HP, et al. Reductions in fatalities following introduction of a reformulated opioid with abuse-deterrent properties. Pharmacoepidemiol Drug Saf. 2013;22:256.
   Google Scholar
• Alpert A, Powell D, Pacula RL. Supply-side drug policy in the presence of substitutes: evidence from the introduction of abuse-deterrent opioids. 2016.
   Google Scholar
• Chilcoat HD, Coplan PM, Harikrishnan V, et al. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin). Drug Alcohol Depend. 2016;165:221–228.
   Google Scholar
• Cepeda MS, Fife D, Chow W, et al. Opioid shopping behavior: how often, how soon, which drugs, and what payment method. J Clin Pharmacol. 2013;53(1):112–117.
   Google Scholar
• Kraft WK, van den Anker JN. Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatr Clin North Am. 2012;59(5):1147–1165.
   Google Scholar
• O’Donnell M, Nassar N, Leonard H, et al. Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics. 2009;123(4):e614–21.
   Google Scholar
• Middleton LS, Nuzzo PA, Lofwall MR, et al. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011;106(8):1460–1473.
   Google Scholar
• Blum K, Modestino EJ, Neary J, et al. Promoting Precision Addiction Management (PAM) to combat the global opioid crisis. Biomed J Sci Tech Res. 2018;2(2):1–4.
   Google Scholar
• Soergel DG, Subach RA, Burnham N, et al. Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain. 2014;155(9):1829–1835.
   Google Scholar
• Siuda ER, Carr R, Rominger DH, et al. Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. Curr Opin Pharmacol. 2017;32:77–84.
   Google Scholar
• Smiley A, McGuire J. Cryoneurolysis for the treatment of sensory nerve pain. Aana J. 2018;86(6):495–503.
   Google Scholar
• Wang TR, Moosa S, Dallapiazza RF, et al. Deep brain stimulation for the treatment of drug addiction. Neurosurg Focus. 2018;45(2):E11–E11.
   Google Scholar
• Bolloni C, Badas P, Corona G, et al. Transcranial magnetic stimulation for the treatment of cocaine addiction: evidence to date. Subst Abuse Rehabil. 2018;9:11–21.
   Google Scholar
• Galaj E, Xi ZX. Potential of cannabinoid receptor ligands as treatment for substance use disorders. CNS Drugs. 2019 Oct; 33(10):1001–1103.
   Google Scholar
• Sierra S, Gupta A, Gomes I, et al. Targeting cannabinoid 1 and delta opioid receptor heteromers alleviates chemotherapy-induced neuropathic pain. ACS Pharmacol Transl Sci. 2019;2(4):219–229.
   Google Scholar
• Lei W, Vekariya RH, Ananthan S, et al. A novel mu-delta opioid agonist demonstrates enhanced efficacy with reduced tolerance and dependence in mouse neuropathic pain models. J Pain. 2019.
   Google Scholar
• Hurd YL, O’Brien CP. Molecular genetics and new medication strategies for opioid addiction. Am J Psychiatry. 2018;175(10):935–942.
   Google Scholar
• Bonese KF, Wainer BH, Fitch FW, et al. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature. 1974;252(5485):708–710.
   Google Scholar
• Bechara A, Berridge KC, Bickel WK, et al. A neurobehavioral approach to addiction: implications for the opioid epidemic and the psychology of addiction. Psychol Sci Public Interest. 2019;20(2):96–127.
   Google Scholar